Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions-Reference-Cited by-同舟云学术

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

Published:2024-03-05 Issue:4 Volume:26 Page:119-131
ISSN:1523-3804
Container-title:Current Atherosclerosis Reports
language:en
Short-container-title:Curr Atheroscler Rep

Author:

Hermel Melody,Chiou Andrew,Minhas Abdul Mannan Khan,Inam Maha,Waldman Carly E.,Youngblood Eventine,Mehta Sandeep,Slipczuk Leandro,Sheikh Sana,Meloche Chelsea,Khoja Adeel,Virani Salim S.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11883-024-01193-8.pdf

Reference22 articles.

1. •Lincoff AM, Brown-Frandsen K, Colhoun HM, et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med https://doi.org/10.1056/NEJMoa2307563. Epub ahead of print. The SELECT study evaluated whether the addition of semaglutide to standard care would be superior to placebo in reducing the risk of major adverse cardiovascular events (MACE) among patients who were overweight or obese with preexisting CVD who did not have diabetes.

2. James S, Erlinge D, Storey RF, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid 3(2), EVIDoa2300286 (2024).

3. Kitt J, Fox R, Frost A, et al. (2023) Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management: the POP-HT randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2023.21523. Epub ahead of print.

4. Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023. 330(21):2075–2083. https://doi.org/10.1001/jama.2023.21835.

5. Liu J, Wang B, Li Y, Yan X, Ge J, Li J. Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial. Am Heart J. 2023;257:93–102.